Table 2.
Typical and Variant APL
| Clinical parameters | Typical APL | Variant APL⁎†‡ | P value |
|---|---|---|---|
| Number of patients | 8 | 8 | |
| Male/female | 3/5 | 5/3 | |
| Age in years at diagnosis, mean (range) | 43 (21–65) | 47 (37–68) | |
| t(15;17) | 8 | 8 | |
| PML-RARα transcript | |||
| bcr1 | 6 (75) | 0 (0) | |
| bcr3 | 1 (13) | 6 (75) | |
| Not done | 1 (13) | 2 (25) | |
| FLT3-ITD, heterozygous | 0 | 8 | |
| Immunophenotype, mean† | |||
| SSC (ratio)‡ | 3.7 (2.6–4.5) | 2.6 (1.6–3.4) | 0.0281 |
| CD34 (%) | 5 (0–17) | 48 (2–90) | 0.0011 |
| c-MPO (%) | 94 (81–98) | 95 (84–99) | 0.3823 |
| HLA-DR (%) | 1 (0–5) | 19 (1–44) | 0.0030 |
| CD13 (%) | 88 (55–99) | 89 (68–99) | 0.9591 |
| CD33 (%) | 97 (94–99) | 91 (37–99) | 0.7984 |
| CD117 (%) | 82 (64–97) | 74 (51–95) | 0.5054 |
| CD11b (%) | 3 (1–5) | 8 (2–33) | 0.1949 |
| CD15 (%) | 4 (1–11) | 2 (0–4) | 0.3823 |
| CD2 (%) | 2 (0–5) | 48 (10–68) | 0.0002 |
| CD56 (%) | 2 (0–8) | 19 (1–64) | 0.0148 |
| CXCR4 (%) | 17 (1–60) | 27 (4–97) | 0.5728 |
| CLIP (%) | 89 (83–98) | 91 (82–98) | 0.3823 |
Genetic aberrancies were determined according to routine cytogenetics and molecular analyses. P values in italics are significant.
APL, acute promyelocytic leukemia; bcr, breakpoint cluster region, an isoform of PML-RARα; FLT3-ITD, internal tandem duplication of the FLT3 gene; PML, promyelocytic leukemia; RAR, retinoic acid receptor; SSC, side scatter.
⁎
Classification of APL subforms according to morphology.5
†
Numbers in brackets represent the percentage or range of each variable within the patient group.
‡
Median SSC ratio between immature myeloid cells and CD45bright lymphocytes in the same sample.